Introduction
Interferons (IFNs) play essential roles in the front line of host defense against viral infections and in immunosurveillance for malignant cells. We previously demonstrated that the type II IFN, interferon-γ (IFNG), induces cytotoxic effects on oligodendroglial progenitor cells (OPC), including slowing of the cell cycle and enhancement of apoptosis, but not on myelin protein-positive mature oligodendrocytes (MO) (Horiuchi et al., 2006) . IFNG is also known to induce surface expression by mature oligodendrocytes of major histocompatibility complex class I molecules (MHC-I) but not of MHC class II molecules (MHC-II) (Suzumura et al., 1986; Calder et al., 1988; Turnley et al., 1991; Satoh et al., 1991; Massa et al., 1993; Tepavcevic and Blakemore, 2005) . This was further supported by the in vivo observation that myelin basic protein (MBP)-positive oligodendrocytes in actively demyelinating multiple sclerosis (MS) lesions were immunohistochemically negative to Ia-antigen (MHC-II), whereas Ia was readily demonstrable on microglia and astrocytes (Lee and Raine 1989; Gobin et al., 2001) . Calder et al. (1988) demonstrated, however, that proliferating OPC are capable of expressing Ia in response to IFNG, but that they become refractory to MHC-II induction by IFNG after terminal differentiation. They suggested that loss of MHC-II inducibility associated with oligodendroglial differentiation might reduce the possibility of autoimmunization by myelin antigens. There has been no study thus far on the molecular basis for this developmental stage-dependent capability of IFNG-induced MHC-II expression in the oligodendroglial lineage.
In general, interferon-β (IFNB), one of type I interferons, is a far less potent inducer of MHC-II than is IFNG, and inhibits IFNG-induced MHC-II expression by some types of cells (Ling et al., 1985; Inaba et al., 1986; Leeuwenberg et al., 1988; Kato et al., 1989; Ransohoff et al., 1991; Lu et al., 1995; Satoh et al.,1995; Weinstock-Guttman et al.,1995) . In contrast to the deleterious effects of IFNG on MS symptoms (Panitch et al., 1987) , IFNB is considered one of the best therapeutic options of relapsing remitting MS to date (Clerico et al., 2008) . The basic mechanisms underlying the beneficial effects of IFNB are still under investigation (Prinz et al., 2008) .
Type I and Type II IFNs recognize distinct receptors, but induce overlapping groups of interferon-stimulated genes (ISGs) stemming from their common dependence on activation of signal transducer and activator of transcription 1 (STAT1) for regulation of ISG transcription. IFNG binds to the type II IFN receptor and exclusively phosphorylates STAT1 through the receptor-associated Janus activated kinases (JAKs), whereas type I IFNs, such as IFNB, recognize the type I IFN receptor, and activate STAT1 and STAT2. Activated STAT1 not only itself functions as a transcription factor after homodimerization, but also forms another transcription complex, interferon-stimulated gene factor 3 (ISGF3), together with activated STAT2 and IRF9/ISGF3G. The specific DNA motif
